<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PATADAY - olopatadine hydrochloride solution/ drops </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">PATADAY™</span> (olopatadine hydrochloride 
ophthalmic solution) 0.2% is a sterile ophthalmic solution containing 
olopatadine for topical administration to the eyes.</p>
<p>Olopatadine hydrochloride is a white, crystalline, water-soluble powder with 
a molecular weight of 373.88 and a molecular formula of C<span class="Sub">21</span>H<span class="Sub">23</span>NO<span class="Sub">3</span>· HCl. 
The chemical structure is presented below:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee6e2161-789b-4ba0-b234-d4b36fe41c94&amp;name=chemical%20structure.jpg"></p>
<p><span class="Bold">Chemical Name:</span> 11-[(Z)-3-(Dimethylamino) 
propylidene]-6-11-dihydrodibenz[b,e] oxepin-2-acetic acid, hydrochloride</p>
<p>Each mL of <span class="Bold">PATADAY™</span> solution contains: <span class="Bold">Active</span>: 2.22 mg olopatadine hydrochloride equivalent to 2 mg 
olopatadine. <span class="Bold">Inactives:</span> povidone; dibasic sodium 
phosphate; sodium chloride; edetate disodium; benzalkonium chloride 0.01% (<span class="Bold">preservative</span>) hydrochloric acid / sodium hydroxide (adjust 
pH); and purified water.</p>
<p>It has a pH of approximately 7 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 300 
mOsm/kg.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Olopatadine is a relatively selective histamine H<span class="Sub">1</span> antagonist and an inhibitor of the release of histamine from 
the mast cells. Decreased chemotaxis and inhibition of eosinophil activation has 
also been demonstrated. Olopatadine is devoid of effects on alpha-adrenergic, 
dopaminergic, and muscarinic type 1 and 2 receptors.</p>
<p>Systemic bioavailability data upon topical ocular administration of <span class="Bold">PATADAY™</span> solution are not available. Following topical ocular 
administration of olopatadine 0.15% ophthalmic solution in man, olopatadine was 
shown to have a low systemic exposure. Two studies in normal volunteers 
(totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic 
solution once every 12 hours for 2 weeks demonstrated plasma concentrations to 
be generally below the quantitation limit of the assay (&lt; 0.5 ng/mL). Samples 
in which olopatadine was quantifiable were typically found within 2 hours of 
dosing and ranged from 0.5 to 1.3 ng/mL. The elimination half-life in plasma 
following oral dosing was 8 to 12 hours, and elimination was predominantly 
through renal excretion. Approximately 60 - 70% of the dose was recovered in the 
urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were 
detected at low concentrations in the urine.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">Results from clinical studies of up to 12 weeks duration 
demonstrate that <span class="Bold">PATADAY™</span> solution when dosed once a day 
is effective in the treatment of <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> associated with allergic 
<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">PATADAY™</span>solution is indicated for the 
treatment of <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any components of this product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">For topical ocular use only. Not for injection or oral use.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>Information for Patients<p class="First">As with any eye drop, to prevent contaminating the dropper tip 
and solution, care should be taken not to touch the eyelids or surrounding areas 
with the dropper tip of the bottle. Keep bottle tightly closed when not in use. 
Patients should be advised not to wear a contact lens if their eye is red.</p>
<p><span class="Bold">PATADAY™</span> (olopatadine hydrochloride ophthalmic 
solution) 0.2% should not be used to treat contact lens related irritation. The 
preservative in <span class="Bold">PATADAY™</span> solution, benzalkonium 
chloride, may be absorbed by soft contact lenses. Patients who wear soft contact 
lenses and <span class="Bold">whose eyes are not red</span>, should be instructed 
to wait at least ten minutes after instilling <span class="Bold">PATADAY™</span> 
(olopatadine hydrochloride ophthalmic solution) 0.2% before they insert their 
contact lenses.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p>Olopatadine administered orally was not carcinogenic in mice and 
rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 
µL drop size and a 50 kg person, these doses were approximately 150,000 and 
50,000 times higher than the maximum recommended ocular human dose (MROHD). No 
mutagenic potential was observed when olopatadine was tested in an <span class="Italics">in vitro</span> bacterial reverse mutation (Ames) test, an <span class="Italics">in vitro</span> mammalian chromosome aberration assay or an <span class="Italics">in vivo</span> mouse micronucleus test. Olopatadine administered 
to male and female rats at oral doses of approximately 100,000 times MROHD level 
resulted in a slight decrease in the fertility index and reduced implantation 
rate; no effects on reproductive function were observed at doses of 
approximately 15,000 times the MROHD level.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy<a href="http://"></a><a href="http://"></a><span class="Bold">Teratogenic effects: Pregnancy 
Category C</span><p>Olopatadine was found not to be teratogenic in rats and rabbits. 
However, rats treated at 600 mg/kg/day, or 150,000 times the MROHD and rabbits 
treated at 400 mg/kg/day, or approximately 100,000 times the MROHD, during 
organogenesis showed a decrease in live fetuses. In addition, rats treated with 
600 mg/kg/day of olopatadine during organogenesis showed a decrease in fetal 
weight. Further, rats treated with 600 mg/kg/day of olopatadine during late 
gestation through the lactation period showed a decrease in neonatal survival 
and body weight.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant 
women. Because animal studies are not always predictive of human responses, this 
drug should be used in pregnant women only if the potential benefit to the 
mother justifies the potential risk to the embryo or fetus.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>Olopatadine has been identified in the milk of nursing rats 
following oral administration. It is not known whether topical ocular 
administration could result in sufficient systemic absorption to produce 
detectable quantities in the human breast milk. Nevertheless, caution should be 
exercised when <span class="Bold">PATADAY™</span> (olopatadine hydrochloride 
ophthalmic solution) 0.2% is administered to a nursing mother.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>Safety and effectiveness in pediatric patients below the age of 3 
years have not been established.</p>
<a href="http://"></a><a href="http://"></a>Geriatric Use<p>No overall differences in safety and effectiveness have been 
observed between elderly and younger patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Symptoms similar to <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> syndrome and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> were reported 
at an incidence of approximately 10%.</p>
<p>The following adverse experiences have been reported in 5% or less of 
patients:</p>
<p><span class="Italics">Ocular:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, burning or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, 
<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, 
<span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, lid <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p><span class="Italics">Non-ocular:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, 
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> and taste 
perversion.</p>
<p>Some of these events were similar to the underlying disease being 
studied.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one drop in each affected eye once a 
day.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">PATADAY™</span>(olopatadine hydrochloride 
ophthalmic solution) 0.2% is supplied in a white, oval, low density polyethylene 
DROP-TAINER® dispenser with a natural low density polyethylene dispensing plug 
and a white polypropylene cap. Tamper evidence is provided with a shrink band 
around the closure and neck area of the package.</p>
<p>NDC 54868-6222-0        2.5 mL fill in 4 mL oval bottle</p>
<a href="http://"></a><a href="http://"></a>Storage<p>Store at 2<span class="Sup">o</span>C to 25<span class="Sup">o</span>C (36<span class="Sup">o</span>F to 77<span class="Sup">o</span>F)</p>
<p>U.S. Patents Nos. 4,871,865; 4,923,892; 5,116,863; 5,641,805; 6,995,186</p>
<p><span class="Bold">Rx Only</span></p>
<p>© 2006 Alcon, Inc.</p>
<br><p><br></p>
<p><span class="Bold">Relabeling of "Additional" barcode label by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK       74146<br></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">PATADAY™</span>(olopatadine hydrochloride ophthalmic solution) 
0.2%</p>
<p>2.5 mL <br></p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee6e2161-789b-4ba0-b234-d4b36fe41c94&amp;name=6222.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PATADAY 		
					</strong><br><span class="contentTableReg">olopatadine hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6222(NDC:0065-0272-25)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OLOPATADINE HYDROCHLORIDE</strong> (OLOPATADINE) </td>
<td class="formItem">OLOPATADINE HYDROCHLORIDE</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6222-0</td>
<td class="formItem">2.5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021545</td>
<td class="formItem">01/03/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>00904221-c0c7-49bd-b00a-8689a2a5a386</div>
<div>Set id: ee6e2161-789b-4ba0-b234-d4b36fe41c94</div>
<div>Version: 1</div>
<div>Effective Time: 20110105</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
